Pharma Stock in Focus After Board Sets Record Date for 1:5 Stock Split and 1:1 Bonus Issue

Synopsis: Anlon Healthcare Limited set Friday, April 24, 2026, as the record date to determine eligible shareholders for its 1:5 stock split and 1:1 bonus issue.

This Micro-cap Pharma stock, engaged in manufacturing and supplying APIs, pharma intermediates, and specialty chemicals to global pharmaceutical, nutraceutical, and healthcare industries, jumped 3.86 percent after the company board set a record date for the 1:5 stock split and 1:1 bonus issue.

With a market capitalization of Rs. 648.45 crores, the share of Anlon Healthcare Limited has reached an intraday high of Rs. 123.75 per equity share, rising nearly 3.86 percent from its previous day’s close price of Rs. 119.15. Since then, the stock has retreated and is currently trading at Rs. 122 per equity share. 

Reason Behind the Surge

Anlon Healthcare Limited’s Board of Directors has fixed Friday, April 24, 2026, as the Record Date for determining the eligibility of shareholders for the allotment of Stock Split and Bonus Issue Shares. 

The company’s board had decided to issue a stock split at a ratio of 1:5, meaning that each equity share’s face value of Rs. 10 will be divided into five equity shares with a share value of Rs. 2 each.

Additionally, Anlon Healthcare Limited’s Board of Directors has also decided to issue bonus shares at a ratio of 1:1, meaning that shareholders will receive one new fully paid-up equity share of Rs. 2 each for every one existing fully paid-up equity share they hold. 

For example, if a shareholder owns 100 shares valued at Rs. 10 each in Anlon Healthcare Limited, after the 1:5 stock split, their total holding will increase to 500 shares with a face value of Rs. 2 each. After this, the shareholder will receive 500 bonus shares, bringing the total holding to 1,000 shares following the 1:1 bonus issue.

Future Outlook

Anlon Healthcare Limited is working to broaden its product range and strengthen its operations to sustain long-term growth. The company intends to introduce seven new APIs in FY2026–27, which will help it enter new therapeutic segments and expand its overall market reach. With a better product mix and improved operating leverage, it targets achieving EBITDA margins of approximately 25-30 percent over the medium term.

In addition, the company is diversifying into industrial and fine chemicals, creating potential new revenue streams and lowering its dependence on pharmaceutical products. Supported by acquisitions and new product launches, management is aiming for a revenue CAGR of around 30 percent over the next three years.

To enable this expansion, the company has planned capital expenditure of $3-5 million during FY2026–27. Post-expansion, its installed capacity is expected to rise to roughly 1,400-1,600 MTPA, while an enhanced R&D pipeline will support continued future growth.

Business Highlights

Anlon Healthcare Limited has established a solid global footprint, with operations spanning 15 countries. The company has submitted 21 Drug Master Files to international regulatory authorities, reflecting its strong emphasis on compliance and quality. It serves a broad customer base of nearly 125 clients worldwide, including both direct and indirect relationships.

The company maintains a well-diversified product portfolio, comprising 65 commercialized products, 28 in the pilot stage, and 49 undergoing laboratory testing. In addition, Anlon Healthcare has a manufacturing capacity of around 400 MTPA, supporting its ongoing production needs and future growth in the pharmaceutical and healthcare space.

Company Overview

Anlon Healthcare Limited was established in 2013 and operates as an Indian pharmaceutical company engaged in the manufacturing and distribution of pharma intermediates and active pharmaceutical ingredients (APIs). It supplies these products to formulators both in India and international markets. The company positions itself as a research-driven and compliance-focused player, catering to manufacturers across medicines, nutraceuticals, personal care, and veterinary segments.

Recent Quarter Results

Coming into financial highlights, Anlon Healthcare Limited’s revenue has increased from Rs. 9.36 crore in Q3 FY25 to Rs. 35.58 crore in Q3 FY26, which has grown by 280.13 percent. The net profit of the company has converted from negative to positive, from a net loss of Rs. 2.49 crore in Q3 FY25 to a net profit of Rs. 5.15 crore in Q3 FY26.

Anlon Healthcare Limited’s revenue has grown at a CAGR of 65.49 percent over the last four years. In terms of return ratios, the company’s ROCE and ROE stand at 24.8 percent and 40.4 percent, respectively. Anlon Healthcare Limited has an earnings per share (EPS) of Rs. 0.27, and its debt-to-equity ratio is 5.15x.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock in Focus After Board Sets Record Date for 1:5 Stock Split and 1:1 Bonus Issue appeared first on Trade Brains.